Q2 Results, Operational Update: Record U.S. Product Sales. NGS Update Should Help Drive Adoption, Procedure Revenue ….
SANUWAVE (OTC:SNWV) reported financial results for their second quarter ending June 30th and provided a business update. As it relates to the financials, while revenue increased significantly from Q1, it nonetheless was, again, relatively disappointing. Down 30% from the prior year, 31% below our estimate and lower than every quarter in 2018, total revenue was a relative dud for the second consecutive period.
But the details behind the numbers paint a better picture than the aggregate topline might suggest. That is because revenue comparables benefited much more from recognition of lump-sum distribution and license fees than did Q2. More importantly, Q2’19 U.S. product sales, at $121k, were the highest (at least) since SNWV began publicly disaggregating by geography (i.e. Q1’17). Given that the U.S. market is where most of the opportunity lies for dermaPACE, coupled with OUS distribution licensing agreements that have largely failed to live up to their implied potential, in the context of growth catalysts, we are much more encouraged by the growth in domestic sales than we are discouraged by the OUS licensing agreements.
Moreover, U.S. device placements continue to track slightly ahead of management’s current-year quarterly guidance which, as a reminder, is for the installed base to reach 15 by close of Q1 (16 actual), 35 by Q2 (36 actual), 70 by Q3 and 110 by the end of 2019. Positive clinical data and favorable patient outcomes appears to remain a major catalyst in driving awareness and initial adoption of dermaPACE in the U.S. With additional studies either ongoing, anticipated to begin shortly and/or expected to come to publication in major peer-reviewed wound care journals, SNWV’s clinical evidence database will continue to build – leveraging of which we expect will remain a key component of their sales and marketing messaging. This, along with further beefing up of the sales force, expansion of the U.S. geographical footprint and, hopefully, further favorable changes to related reimbursement, represent potentially potent catalysts to driving awareness of dermaPACE and steepening the placement rate.
The combination of a growing installed base and contribution from procedural volume has the potential to create somewhat of a multiplier effect and result in significant acceleration of U.S. revenue. The recent update from a major Medicare contractor, which we discuss below, could be the initial spark to procedural revenue.
Major Regional CMS Contractor Coverage Update Should Benefit Adoption of dermaPACE
While we have made some downward revisions to our OUS sales, with SNWV’s mid-August announcement that Medicare regional contractor, National Government Services, Inc. (NGS), updated coverage guidance for two specific codes that will cover the use of dermaPACE for the treatment of DFU’s (applicable to certain conditions), we are more encouraged than ever by the domestic opportunity. Specifically, as it relates to NGSs update, per SNWV’s 8/14/19 PR, effective July 1, 2019, CPT codes 0512T and 0513T (Extracorporeal shockwave therapy for integumentary wound healing, high energy) have been reclassified from Group 1 (i.e. ‘not medically necessary’) to CPT 3 (i.e. ‘individually reviewed to determine medical necessity’). NGS’s updated coverage guidance is available here.
NGS administers benefits to 7M A/B Medicare members in 10 states; NY, ME, RI, VT, CT, NH, MA, MN, WI, and IL which, in aggregate (per SNWV, which cites the American Diabetes Association), represents 47.5M people including 5.8M with diabetes. SNWV estimates that more than 600k people fit the treatment profile for dermaPACE in these 10 states, representing what they calculate to be a total market opportunity of more than $1B.
We had not anticipated this level of coverage nearly this soon, particularly for such a large covered-lives population. While NGS’ update does not guarantee every claim will be paid, it should provide much more certainty than if the procedure was considered not medically necessary. SNWV management indicated on the Q2 call that as long as providers only use dermaPACE for its FDA indicated uses, providers should have success in receiving reimbursement under these codes.
Per CMS.gov, these two codes are not currently listed in the Medicare fee schedule but instead are contractor priced (i.e. NGS, in this case). While we will not know how ‘robust’ (i.e. average $ payment and proportion of valid claims that are paid ) NGS reimbursement will be, management noted that Medicare will pay $314 per procedure and, again, indicated that they expect most claims will be paid (without having doctors having to endure repeated denials and rebillings). As is commonplace, private payers, if they follow NGS’ lead (a topic which we will be eager to hear updates about), could be expected to pay a significantly higher rate than Medicare.
View Exhibit I
Importantly, management believes even the Medicare rate is sufficient to drive interest, adoption and utilization of dermaPACE by clinicians. We think this is a reasonable assumption, particularly given the lack of capital risk to the provider (as SNWV places the devices free of charge). And while SNWV did not increase their current-year dermaPACE placement guidance (110 expected in FY2019, including current installed base of 36) as a result of this coverage update, they do anticipate an earlier ramp in procedural revenue.
The reimbursement update also means SNWV will add personnel – including sales staff and clinical trainers to cover these ten states. There may be incremental headcount additions to support positions such as billing and collections. Noteworthy is that the company will not shift significant resources from their initial targeted regions in the U.S. (Texas, California, North and South Carolina, Pennsylvania and Illinois) – perhaps an indication that they are having ‘sufficient’ commercial success in these areas.
Q2 revenue was $317k ($128k U.S., $190k OUS), down 30% yoy, up 78% from Q1’19 and well below our $460k estimate.
U.S. sales were $127k, accounting for 40% of total revenue, and included $121k and $6k of product and license revenue, respectively. Total U.S. sales increased from $25k and $24k in Q2’18 and Q1’19, respectively. U.S. product sales reached a new quarterly high and were up from $19k and $18k in prior year and 3-month periods, respectively.
Meanwhile, international sales were $190k, down 56% yoy, up 24% qoq, and consisted of $100k (-49% yoy, +114% qoq) of product sales, $61k (-69% yoy, -39% qoq) of license fees and $30k (-15% yoy, +315% qoq) of ‘other’. OUS sales were disappointing for the second consecutive quarter and averaged just $172k/quarter during 1H’19, compared to $179k/qtr in FY2017 and $404k/qtr in 2018. Not only has OUS product sales growth slowed, but we think it is becoming more apparent that the distribution license agreements are not working out as planned.
Last year MundiMed defaulted on their JV agreement with SNWV (for commercialization in Brazil). More recently, it appears that Johnfk Medical Inc. (covering Taiwan, Singapore, Malaysia, Brunie, Cambodia, Myanmar, Laos, Indonesia, Thailand, Philippines and Vietnam) bowed out, defaulting on their agreement earlier this year. Per management, these and others like it, were expected to bring in potentially many millions of dollars in license fees and sales-related revenues and reduce the company’s reliance on external capital to fund operations. However, given recent history, we think there’s enough writing on the wall to suggest these types of agreements were either too early, poorly crafted or otherwise highly susceptible to failure. As such, we have removed all assumed contribution from these agreements from our model. We, however, remain hopeful that the U.S. regulatory clearance and eventual ramp in domestic adoption and utilization will (eventually) create a halo effect overseas and be a significant catalyst in driving international revenue.
SNWV recently brought in Alira Health to lead its European commercial efforts. And, we reiterate that recent expansion of SNWV’s OUS footprint, expanding ‘label’ from orthopedics-only to, more recently, include wound treatment in several territories and new distributor relationships are all potential catalysts that could have a positive impact on international revenue growth going forward. Certainly, FDA clearance, while largely meaningless from an OUS regulatory standpoint, can act as a proxy ‘stamp of approval’ and prove an important and influential marketing message and help drive adoption. New clinical studies have also recently commenced, positive results of which could also aid in adoption and utilization. Among these are a dose-optimization study in Poland (as well as a U.S.-based perfusion study), which commenced in April 2019 and is expected to complete later this year.
We should provide some context, however, as while we have been disappointed by the lack of consistent growth in international sales, we have always viewed the U.S. market as representing the vast majority of the commercial opportunity for dermaPACE. Management has indicated that the OUS business is profitable (in at least some countries) and that they believe it will grow. But OUS product sales have all but stalled and the international growth that was supposed to materialize years ago, didn’t. While we do believe that there are reasonable reasons why OUS could pick up (explained earlier), given the developing U.S. opportunity (particularly following the update by NGS) and the resources (capital, time, leadership, etc) required to take advantage of it, we wonder if another serious strategic review of OUS operations is warranted.
Cash balance was $155k at quarter end. Cash used in operating activities was $2.1M and $3.4M ($1.9M and $3.7M) in the three and six months ending 6/30/19, compared to and inflow of $250k and (an outflow of) $1.9M in the comparable prior year periods. Management is guiding for monthly cash burn of about $300k for the remainder of 2019.
U.S. roll-out underway…
As noted, management mentioned on the call that they already have 36 units placed in the U.S. via their direct efforts (up from 16 at the close of Q1’19). They continue to guide for a U.S. installed base of at least 70 units by the end of Q3 and 110 by the close of 2019. Management further disclosed that to-date, 116 users (i.e. providers) have been trained and certified to use dermaPACE and 130 patients were treated during Q2. They are well on their way to meeting both their installed base and trained-users guidance, the latter which they aim to have 300 by the end of this year.
As a reminder, SNWV places the devices for free and generates revenue when they are used – which means it is critical that not only are devices placed, but that users are trained. Management noted that their main focus for 2019 is on steepening the placement rate, while a more determined focus on driving utilization will happen in 2020 – although the (unexpected) NGS coding change, effective July 1, 2019, may mean that procedural volume may begin and steepen earlier than previously anticipated.
A CPT III tracking code became effective January 1, 2019. Clinicians will use this to submit for reimbursement (which they may or may not receive) and most payers will use it to monitor usage and for making policy, reimbursement and rate decisions (this is not as applicable to NGS as reimbursement should eventually be relatively seamless). As we have noted in prior updates, novel medical devices, such as dermaPACE often initially go to market in the U.S. sans-dedicated Medicare reimbursement. While we think that providers (perhaps, particularly influential KOLs) may have some success billing under this CPT III, we expect spotty reimbursement, at best, initially or at least until there is more usage data and perhaps, until following conclusion of supportive post-approval clinical utility and pharmacoeconomic studies. Eventual issuance of a CPT I code will likely be the goal, although that could be a years-long process and will undoubtedly require sufficient usage and economic data.
SNWV mentioned that they have brought on consultants to help with their initial reimbursement strategy – which will include picking certain regional payers and engaging with an evidence-based approach. Initial discussions with private insurers and MACs (i.e. regional Medicare) are underway – which presumably helped facilitate the favorable change by NGS. We will continue to be eager to hear updates about the outcome of discussions with payers.
As it relates to NGS, given that reimbursement claims will be ‘individually reviewed to determine medical necessity’, payment is not guaranteed. But we expect it should provide much more certainty than if the procedure was considered not medically necessary. And while, ‘individually reviewed to determine medical necessity’ may mean that most or all initial claims are looked through with a fine toothed comb, we think it is reasonable to believe that as each provider builds trust with a history of valid claims that it will speed and ease the billing and review process and reduce risk of claim denials. Assuming that proves to be true, it will directly benefit procedural revenue and, given its validation of the economics of dermaPACE DFU treatment in the U.S., should almost certainly benefit adoption as well.
SNWV has indicated that they will conduct an initial pharmacoeconomic study and that results will be used to help support their case to these regional payers. Importantly, a manuscript of the two pivotal (initial and supplemental) studies used as primary support for SNWV’s application seeking FDA clearance of dermaPACE was published in the peer-reviewed Journal of Wound Care in December 2018. This is a significant event in our opinion, particularly in the context of communicating the benefits and utility of dermaPACE in treating DFUs at the clinician level. Other post-marketing studies, aimed at clinician adoption and utilization, are also planned in the U.S.
In fact a skin perfusion study, being conducted in New Jersey and California, commenced in April 2019. The study will evaluate the effects of their dermaPACE technology on local skin perfusion (blood flow) and its effect on healing DFU’s. Additional studies, aimed at supporting the U.S. roll-out, are also expected to begin during 2019. These are topics that we will be eager to hear updates on given their potential outsized influence on whether a provider chooses to use, or a payor chooses to reimburse for, a particular modality or therapy.
SNWV’s initial commercialization territories in the U.S., which they chose due to their potential receptiveness to adoption and use of dermaPACE (under a CPT III code), are Texas, California, North and South Carolina, Pennsylvania and Illinois (these are the initial territories and are in addition to the 10 NGS states). The criteria under which these areas were chosen includes population density, presence of doctors with high volume of DFU patients and payors that have shown to be more amenable to reimbursing for novel technologies.
Management indicated on their recent earnings calls that initial feedback from U.S. clinicians has been positive. Among the feedback were comments from doctors of ‘great results’ with using dermaPACE for chronic wounds, that safety of the device was noteworthy, plans to use dermaPACE for DFUs in conjunction with other therapies and use of dermaPACE when other therapies have failed.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.